Burns J W & Co. Inc. NY Buys 175 Shares of Novo Nordisk A/S (NYSE:NVO)

Burns J W & Co. Inc. NY increased its position in Novo Nordisk A/S (NYSE:NVO) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,605 shares of the company’s stock after buying an additional 175 shares during the period. Burns J W & Co. Inc. NY’s holdings in Novo Nordisk A/S were worth $482,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Eastern Bank increased its holdings in shares of Novo Nordisk A/S by 0.6% during the fourth quarter. Eastern Bank now owns 90,450 shares of the company’s stock valued at $7,781,000 after acquiring an additional 520 shares in the last quarter. Grassi Investment Management bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $215,000. JCIC Asset Management Inc. raised its holdings in Novo Nordisk A/S by 1.8% during the fourth quarter. JCIC Asset Management Inc. now owns 37,207 shares of the company’s stock worth $3,201,000 after buying an additional 665 shares during the last quarter. Cooper Financial Group lifted its stake in shares of Novo Nordisk A/S by 5.7% in the fourth quarter. Cooper Financial Group now owns 11,072 shares of the company’s stock valued at $952,000 after buying an additional 593 shares in the last quarter. Finally, Wedmont Private Capital increased its position in shares of Novo Nordisk A/S by 3.0% during the fourth quarter. Wedmont Private Capital now owns 11,450 shares of the company’s stock worth $988,000 after acquiring an additional 330 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded down $1.83 during midday trading on Monday, hitting $84.43. The company’s stock had a trading volume of 7,237,434 shares, compared to its average volume of 7,400,001. The stock has a fifty day moving average price of $100.35 and a 200 day moving average price of $119.04. The firm has a market capitalization of $378.88 billion, a price-to-earnings ratio of 27.32, a P/E/G ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.